UPDATE: INVICTUS NASDAQ APPLICATION AND SHARE CONSOLIDATION

Date : 01/21/2019 @ 6:52PM
Source :InvestorsHub NewsWire
Stock : Invictus MD Strategies Corp (GENE)
Quote : 0.38  0.0 (0.00%) @ 8:59PM

UPDATE: INVICTUS NASDAQ APPLICATION AND SHARE CONSOLIDATION



 


Vancouver, BC -- January 21, 2019 -- InvestorsHub NewsWire -- INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) announced today an update to its intention to proceed with a consolidation of its issued and outstanding shares with a newly proposed reduced share consolidation ratio of one new share for every five old shares (1:5) in connection with its proposed listing on Nasdaq Stock Market LLC ("Nasdaq"). The proposed reduced share consolidation ratio replaces the original consideration on the basis of one new share for seven old shares (1:7) (see press release dated January 17, 2019).

The purpose of the consolidation is to increase the Company’s common share price to be in compliance with Nasdaq’s minimum share price listing requirement of USD $3.00 (CAD $3.98). Management believes this reduced ratio is sufficient to achieve Nasdaq’s minimum threshold. At Friday’s closing share price of CAD 1.06 (USD 0.80) on January 18, 2019, a 5:1 consolidation represents a new Company share valued at CAD 5.30 (US 3.99).

Most importantly, while investors will hold fewer Invictus shares after the consolidation, each shareholder’s total invested value, percentage ownership in the Company and proportional voting power will remain unchanged.

The United States represents the deepest pool of investor capital in the world with Nasdaq featuring heavily. Invictus’ intended participation on the Nasdaq represents a move to increase its global visibility and liquidity, and for inclusion into indices which are tracked by buy-side institutions like the Standard & Poor’s and Russell indexes.

In addition to the intended Nasdaq listing, Invictus’ shares will continue to trade on the TSX Venture Exchange under the ticker symbol "GENE", and on the Frankfurt Stock Exchange under the ticker symbol "8IS1".

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director

Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(833) 879-4363

About Invictus

Invictus is a global cannabis company offering a selection of products under a wide range of brands. Our integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.

Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer. To meet growing demand, Invictus is expanding its cultivation footprint, with three cannabis production facilities licensed under the Cannabis Act and Cannabis Regulations in Canada. To accommodate international sales, Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd. (“Acreage Pharms”), has designed and is currently building its Phase 3 purpose-built cultivation facility to be European Union Good Manufacturing Practices (“EU-GMP”) compliant. The Company is targeting up to 50 percent of production to medical cannabis. To ensure consistency in quality and supply, Invictus maintains all aspects of the growing process through its subsidiary, Future Harvest Development Ltd. (“Future Harvest”), a high-quality fertilizer and nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 70 Health Canada approved strains and a multifaceted distribution strategy including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. For more information visit www.invictus-md.com.


Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including statements with respect to the consolidation of the Company's common shares; and the timing, receipt of regulatory approval for, and listing of the Company's common shares on NASDAQ and the filing of a Form 40-F Registration Statement with the United States Securities and Exchange Commission are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the  Company will be successful in completing the consolidation and obtaining NASDAQ approval and all necessary regulatory approvals for the listing of its common shares on NASDAQ. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the Company will not be successful in completing the Consolidation or obtaining the necessary regulatory approvals to complete the listing on NASDAQ. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 

Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Invictus MD Strategies Charts.

Invictus MD Strategies (TSXV:GENE)
Intraday Stock Chart

Today : Sunday 21 July 2019

Click Here for more Invictus MD Strategies Charts.

Latest TSXV:GENE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.